Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

MMWR Report On Gonorrhea And Chlamydia Incidence Among MSM Spurs AHF To Call For FDA Approval Of Newer Testing Technologies
On the heels of the publication today of a landmark, five city US study of gonorrhea and Chlamydia infections and related testing protocols among populations of at-risk men-who-have-sex-with-men (MSM), the AIDS Healthcare Foundation (AHF)-a clinical participant in the research trial component in Los Angeles- called on the Food and Drug Administration (FDA) to fast track approval of newer and alternative testing technologies highlighted in the study for use in the diagnosis of gonorrhea and Chlamydia infections among high-risk populations. The study, "Clinic-based Testing for Rectal and Pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis Infections by Community-based Organizations-Five Cities, United States, 2007" published in the respected Centers for Disease Control"s (CDC) Morbidity and Mortality Weekly Report (MMWR, July 9, 2009), found that one testing protocol, nucleic acid amplification (NAA), is, "ò€¦generally more sensitive and favored by most experts," particularly for extragenital testing (for rectal and pharyngeal specimens); however, "NAA tests have not been cleared by the Food and Drug Administration (FDA) for the diagnosisò€¦and may not be marketed for that purpose."
generic viagra online
Most Women Would Choose Surgical Profession Again
Most women surgeons would choose their career again, although many would favor more options for part-time or other alternative work schedules, according to a report in the July issue of Archives of Surgery, one of the JAMA/Archives journals.
News of the day
Glutamine Supplements Show Promise In Treating Stomach Ulcers
Nearly 20 years ago, it was discovered that bacteria known as Helicobacter pylori were responsible for stomach ulcers. Since then, antibiotics have become the primary therapy used to combat the H. pylori infection, which affects approximately six percent of the world population and is also a primary cause of stomach cancer. But today the bacteria is growing increasingly resistant to antibiotics.
Nutrition

New Animal Study Of Rexahn's Serdaxin™ Shows Drug's Promise To Treat Anxiety And Depression With Minimal Side Effects

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), announced the results of a wide-ranging animal study offering more evidence that Serdaxin™ may be an effective therapeutic for the treatment of anxiety disorders in humans. Serdaxin is Rexahn"s leading anxiety and depression drug candidate, and is currently in Phase II clinical trials. The research tested Clavulanic acid, the primary compound in Serdaxin, across three mammalian species - hamsters, rats and cotton top tamarin monkeys - and was carried out at the University of Massachusetts and the University of Wisconsin. Results of the study reveal that Clavulanic acid is highly potent, has a unique profile, and has anti-anxiety "activity unlike any of the commonly prescribed drugs used to treat anxiety disorders." The study (to be published in the journal of Pharmacology, Biochemistry and Behavior in the August 2009 issue) "Clavulanic acid: A competitive inhibitor of beta-lactamases with novel anxiolytic-like activity and minimal side effects " found that Serdaxin exerts strong anti-anxiety and anti-depression effects in all three animal species at low doses and without unwanted side effects. Of particular interest, when the study compared Serdaxin to commonly prescribed psychoactive drugs (benzodiazepines), is that Serdaxin was found to have an extremely favorable profile. For example, Serdaxin was able to provide the desired anti-anxiety and anti-depression effects without impaired motor activity and loss in learning and memory. Moreover, Serdaxin was able to achieve its desired efficacy at doses as low as 1/100th of conventional psychoactive drugs. "This wide-ranging study offers further evidence that Serdaxin holds the promise to change the treatment paradigm for anxiety and depression," said Dr. Chang H. Ahn, Chairman and CEO of Rexahn. "Conventional psychoactive drugs have slow onset of activity and major unwanted side effects, such as loss in memory, impaired motor activity, weight gain or lack of libido. Due to Serdaxin"s unique mechanism of action on the brain, it has the potential to become the first therapeutic capable of treating anxiety and depression without causing these negative side effects." About Serdaxin SerdaxinTM is a potential market leading CNS neuroprotective agent and antidepressant. Among lead indications, we are investigating Serdaxin for depression in Phase II clinical trials. Serdaxin may achieve greater and broader therapeutic coverage, and appears to have no serious side effects such as nausea, vomiting, insomnia, weight gain, sexual dysfunction, cognitive deficit or motor impairment that are linked to existing antidepressant drugs. Serdaxin has well-established and excellent human safety. In preclinical studies, Serdaxin had onset of action in less than two days, whereas currently marketed drugs take several weeks. Based on its novel mechanism affecting both depression and neuroprotection, Serdaxin is a potential treatment for multiple CNS disorders such as Parkinson"s disease (PD) and Alzheimer"s disease, where the patients suffer from neurodegeneration, and depression as a co-morbidity. Rexahn has multiple clinical programs planned for Serdaxin including depression and anxiety disorders, Parkinson"s disease, Alzheimer"s and neurodegenerative illnesses, neuroprotection and biodefense uses. Rexahn Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009